APA (7th ed.) Citation

E, A., C, G., A, B., & S, S. (2026). Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clinical ophthalmology (Auckland, N.Z.), 20, 596406. https://doi.org/10.2147/OPTH.S596406

Chicago Style (17th ed.) Citation

E, Ahmed, Goodchild C, Bisoukis A, and Salvatore S. "Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration." Clinical Ophthalmology (Auckland, N.Z.) 20 (2026): 596406. https://doi.org/10.2147/OPTH.S596406.

MLA (9th ed.) Citation

E, Ahmed, et al. "Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration." Clinical Ophthalmology (Auckland, N.Z.), vol. 20, 2026, p. 596406, https://doi.org/10.2147/OPTH.S596406.